参考文献/References:
[1].Robinson JC,Pugliese SC,Fox DL,et al.Anticoagulation in pulmonary arterial hypertension[J]．Curr Hypertens Rep,2016,18(6):47.
[2].[2] Zhang YJ,Wang N,Gu ZC,et al. A network meta-analysis for safety of endothelin receptor antagonists in pulmonary arterial hypertension[J]. Cardiovasc Diagn Ther,2019,9(3):239-249.
[3].Chen X,Zhai Z,?Huang K,et al.Bosentan therapy for pulmonary arterial hypertension and chronic thrombosis pulmonary hypertension:a systemic review and meta-analysis[J]. Clin Respir J,2018,12(6):2065-2074.
[4].Galiè N,Humbert M,Vachiery JL,et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension[J].Eur Respir J ,2015,46(4):903-975.
[5].Chu JW ,Kao PN,Faul JL,et al. High prevalence of autoimmune thyroid disease in pulmonary arterial hypertension[J]. Chest,2002,122(5):1668-1673.
[6].[6] Scarneciu CC,Sangeorzan L,Popescu M,et al. The relation of dependency and the predictive potential of several factors possibly involved in determining pulmonary hypertension in Graves’ disease[J]. Pak J Med Sci,2018,34(3):583-589.
[7].[7] Krieg VJ,Hobohm L,Liebetrau C,et al. Risk factors for chronic thrombosis pulmonary hypertension—Importance of thyroid disease and function[J]. Thromb Res, 2020,185:20-26.
[8].[8] Zuhur SS,Baykiz D,Kara SP,et al. Relationship among pulmonary hypertension, autoimmunity,thyroid hormones and dyspnea in patients with hyperthyroidism[J]. Am J Med Sci,2017,353(4):374-380.
[9].[9] Bingjie W,Jingjing J,Minghui G,et al. Serum-free thyroxine levels were associated with pulmonary hypertension and pulmonary artery systolic pressure in euthyroid patients with coronary artery disease[J]. Int J Endocrinol,2017,2017:4832608.
[10].[10] Tudoran C,Tudoran M,Vlad M,et al.Echocardiographic evolution of pulmonary hypertension in female patients with hyperthyroidism[J]. Anatol J Cardiol,2018,20(3):174-181.
[11].[11] Fukusumi M,Iidaka T,Mouri A,et al. Respiratory failure associated with hypoventilation in a patient with severe hypothyroidism[J]. Respirol Case Rep,2014, 2(2):79-80.
[12].[12] Bhandari L,Tyagi R,Gaur N,et al. Pulmonary function tests in thyroid disorders[J]. Natl J Physiol Pharm Pharmacol,2019,9(8):719-722.
[13].[13] Hillman NH,Kallapur SG,Jobe AH. Physiology of transition from intrauterine to extrauterine life[J]. Clin Perinatol,2012,39(4):769-783.
[14].[14] 孙茜,高杨,王艳,等.肺动脉高压合并甲状腺功能异常临床特点分析[J].心肺血管病杂志,2020,39(2):143-146.
[15].[15] Schmohl KA,Mueller AM,Dohmann M,et al. Integrin αvβ3-mediated effects of thyroid hormones on mesenchymal stem cells in tumor angiogenesis[J]. Thyroid,2019,29(12):1843-1857.
[16].[16] Pereira-Castro J,Brás-Silva C,Fontes-Sousa AP . Novel insights into the role of urotensin Ⅱ in cardiovascular disease[J]. Drug Discov Today,2019,24(11):2170-2180.
[17].[17] Taglieri L,Nardo T,Vicinanza R,et al.Thyroid hormone regulates fibronectin expression through the activation of the hypoxia inducible factor 1[J].Biochem Biophys Res Commun,2017,493(3):1304-1310.
[18].[18] Ortiz VD,de Castro AL,Campos C,et al.Effects of thyroid hormones on aortic tissue after myocardial infarction in rats[J].Eur J Clin Pharmacol,2016,791:788-793.
[19].[19] Desideri G,Bocale R,Damore AM,et al. Thyroid hormones modulate uric acid metabolism in patients with recent onset subclinical hypothyroidism by improving insulin sensitivity[J]. Intern Emerg Med,2020,15(1):67-71.
[20].[20] Liu X,Zhang J,Meng Z,et al. Gender impact on the correlations between Graves’ hyperthyroidism and hyperuricemia in Chinese[J].Ir J Med Sci,2019,188(3):843-848.
[21].[21] Sandoval J,Del Valle-Mondragón L,Masso F,et al. Angiotensin converting enzyme 2 and angiotensin(1–7) axis in pulmonary arterial hypertension[J].Eur Respir J,2020,56(1):1902416.
[22].[22] Fukuyama K,Ichiki T,Imayama I,et al.Thyroid hormone inhibits vascular remodeling through suppression of cAMP response element binding protein activity[J]. Arterioscler Thromb Vasc Biol,2006,26(9):2049-2055.
[23].[23] Marvisi M,Balzarini L,Mancini C,et al. Thyroid gland and pulmonary hypertension. What’s the link?[J]. Panminerva Med,2013,55(1):93-97.
[24].[24] Yousefzadeh N,Jeddi S,Ghasemi A. Impaired cardiovascular function in male rats with hypo- and hyperthyroidism:involvement of imbalanced nitric oxide synthase levels[J]. Endocr Metab Immune Disord Drug Targets,2020 May 8.DOI:10.2174/1871530320666200508115543.Epub ahead of print.
[25].[25] Osmak-Tizon L,Poussier M,Cottin Y,et al. Non-genomic actions of thyroid hormones:molecular aspects[J]. Arch Cardiovasc Dis,2014,107(4):207-211.
[26].[26] Bano A,Chaker L,de Maat MPM,et al. Thyroid function and cardiovascular disease:the mediating role of coagulation factors[J]. J Clin Endocrinol Metab,2019,104(8):3203-3212.
[27].[27] Pop?awska-KitaA,SiewkoK,Telejko B,et al. The changes in the endothelial function and haemostatic and inflammatory parameters in subclinical and overt hyperthyroidism[J].Int J Endocrinol,2013,2013:981638.
[28].[28] Davis PJ,Mousa SA,Schechter GP. New interfaces of thyroid hormone actions with blood coagulation and thrombosis[J]. Clin Appl Thromb Hemost,2018,24(7):1014-1019.
[29].[29] Wu B,Jiang J,Gui M,et al. Serum-free thyroxine levels were associated with pulmonary hypertension and pulmonary artery systolic pressure in euthyroid patients with coronary artery disease[J]. Int J Endocrinol,2017,2017:4832608.
[30].[30] Li C,Liu P,Song R,et al.Immune cells and autoantibodies in pulmonary arterial hypertension[J]. Acta Biochim Biophys Sin(Shanghai) ,2017,49(12):1047-1057.
[31].[31] Sugiura T,Yamanaka S,Takeuchi H,et al. Autoimmunity and pulmonary hypertension in patients with Graves’ disease[J]. Heart Vessels,2015,30(5):642-646.
[32].[32] Costa CCB,Medeiros M,Watanabe K,et al. Hashimoto thyroiditis may be associated with a subset of patients with systemic sclerosis with pulmonary hypertension[J]. Rev Bras Reumatol,2014,54(5):366-370.
[33].[33] Oldham JM,Kumar D,Lee C,et al.Thyroid disease is prevalent and predicts survival in patients with idiopathic pulmonary fibrosis[J]. Chest,2015,148(3):692-700.
[34].[34] Patel N,Inder WJ,Sullivan C,et al. An audit of amiodarone-induced thyrotoxicosis—do anti-thyroid drugs alone provide adequate treatment?[J].Heart Lung Circ,2014,23(6):549-554.
[35].[35] Chainy GBN，Sahoo DK. Hormones and oxidative stress:an overview[J]. Free Radic Res,2020,54(1):1-26.
[36].[36] Tian X，Li N，Su R，et al. Selenium supplementation may decrease thyroid peroxidase antibody titer via reducing oxidative stress in euthyroid patients with autoimmune thyroiditis[J]. Int J Endocrinol,2020,2020:9210572.
[37].[37] Gu Y,Meng G,Zhang Q,et al. Thyroid function and lipid profile in euthyroid adults:the TCLSIH cohort study[J]. Endocrine,2020,70(1):107-114.
[38].[38] 柯蕊,吴媛媛,王贵佐,等.胰岛素抵抗与肺动脉高压关系的研究进展[J].南方医科大学学报,2015,35(2):301-305.
[39].[39] Simpson CE,Chen JY,Damico RL,et al. Cellular sources of interleukin-6 and associations with clinical phenotypes and outcomes in pulmonary arterial hypertension[J]. Eur Respir J,2020,55(4):1901761.
[40].[40] 龙俊蓉,刘盛权,唐芬,等.硫化氢下调STAT3改善MMPs/TIMPs失调及高甲状腺激素诱导的心肌纤维化[J].中国医院药学杂志,2018,38(7):697-700,707.
[41].[41] Richter MJ,Sommer N,Schermuly R,et al. The prognostic impact of thyroid function in pulmonary hypertension[J].J Heart Lung Transplant,2016,35(12):1427-1434.
[42].[42] 聂美玲,刘乐,马涵英.低T_3综合征对左心疾病相关肺动脉高压患者再住院及死亡的影响研究[J].中国全科医学,2018,21(14):1666-1671.
相似文献/References:
[1]孟晓冬,单福祥,综述,等.肺动脉高压治疗进展[J].心血管病学进展,2016,(3):319.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.028]
MENG Xiaodong,SHAN Fuxiang,WANG Yanhui.Advances in Research of Pulmonary Hypertension[J].Advances in Cardiovascular Diseases,2016,(3):319.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.028]
[2]张艺韬,综述,曾伟杰,等.左心疾病相关肺动脉高压流行病学[J].心血管病学进展,2016,(4):333.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.002]
ZHANG Yitao,ZENG Weijie,CHENG Kanglin.Epidemiology of Pulmonary Hypertension due to Left Heart Disease[J].Advances in Cardiovascular Diseases,2016,(3):333.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.002]
[3]汪汉,刘英杰,王燕凤.长链非编码RNA与肺动脉高压[J].心血管病学进展,2019,(6):898.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.015]
WANG Han,LIU Yingjie,WANG Yanfeng.Long Non-coding RNA in Pulmonary Arterial Hypertension[J].Advances in Cardiovascular Diseases,2019,(3):898.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.015]
[4]汪汉 邓祁 刘英杰.系统性红斑狼疮相关肺动脉高压的诊断、治疗及预后[J].心血管病学进展,2019,(8):1142.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.018]
WANG Han,DENG Qi,LIU Yingjie.Diagnosis,Treatment and Prognosis of Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus[J].Advances in Cardiovascular Diseases,2019,(3):1142.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.018]
[5]段宇 贾静 步睿 李涛 韦宏.急性伊洛前列素吸入对肺动脉高压患者右心室功能的影响[J].心血管病学进展,2019,(9):1319.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.034]
DUAN Yu,JIA Jing,BU Rui,et al.The Effect of Acute Iloprost Inhalation on Right Ventricular Function in Pulmonary Arterial Hypertension[J].Advances in Cardiovascular Diseases,2019,(3):1319.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.034]
[6]查玉杰 何庆.肺动脉高压发生发展中的相关因子[J].心血管病学进展,2020,(2):192.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.024]
ZHA YujieHE Qing.The Relevant Factors in the Development of Pulmonary Hypertension[J].Advances in Cardiovascular Diseases,2020,(3):192.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.024]
[7]朱珊英,朱国斌.肺动脉高压发病机制新进展[J].心血管病学进展,2020,(3):292.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.019]
ZHU Shanying,ZHU Guobin.Pathogenesis of Pulmonary Hypertension[J].Advances in Cardiovascular Diseases,2020,(3):292.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.019]
[8]韩柯,孟祥光,赵育洁.趋化因子及其受体在肺动脉高压中的研究进展[J].心血管病学进展,2020,(3):296.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.020]
HAN Ke,MENG Xiangguang,ZHAO Yujie.Chemokines and Their Receptors in Pulmonary Arterial Hypertension[J].Advances in Cardiovascular Diseases,2020,(3):296.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.020]
[9]刘超 曲杰 王明娟 徐倩 范彦芳 周晓慧 单伟超.肺动脉高压对扩张型心肌病预后的影响[J].心血管病学进展,2020,(4):424.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.023]
LIU ChaoQU JieWANG MingjuanXU QianFAN YanfangZHOU XiaohuiSAN Weichao.The Effect of Pulmonary Hypertension on the Prognosis of Dilated Cardiomyopathy[J].Advances in Cardiovascular Diseases,2020,(3):424.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.023]
[10]向杰 刘明鑫 张伟 黄从新.基于生物信息学分析探究肺动脉高压关键基因和通路[J].心血管病学进展,2020,(4):428.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.024]
Xiang JieLiu MingxinZhang WeiHuang Congxin.Bioinformatics Analysis of Key Genes and Pathways in Pulmonary Arterial Hypertension[J].Advances in Cardiovascular Diseases,2020,(3):428.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.024]